Tandem Diabetes Care (FRA:TD5A) EBIT : €-197.4 Mil (TTM As of Dec. 2023)

View and export this data going back to 2013. Start your Free Trial

What is Tandem Diabetes Care EBIT?

Tandem Diabetes Care's earnings before interest and taxes (EBIT) for the three months ended in Dec. 2023 was €-27.6 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2023 was €-197.4 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Tandem Diabetes Care's annualized ROC % for the quarter that ended in Dec. 2023 was -33.09%. Tandem Diabetes Care's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -45.67%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Tandem Diabetes Care's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -9.03%.

Tandem Diabetes Care EBIT Historical Data

The historical data trend for Tandem Diabetes Care's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tandem Diabetes Care EBIT Chart

Tandem Diabetes Care Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT

Get a 7-Day Free Trial

-22.14

-19.83

17.89

-83.58

-195.04

Tandem Diabetes Care Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EBIT	Get a 7-Day Free Trial															-14.19	-114.42	-30.48	-24.92	-27.61

Competitive Comparison of Tandem Diabetes Care's EBIT

For the Medical Devices subindustry, Tandem Diabetes Care's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Tandem Diabetes Care's EV-to-EBIT Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Tandem Diabetes Care's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Tandem Diabetes Care's EV-to-EBIT falls into.

Tandem Diabetes Care EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-197.4 Mil.

Tandem Diabetes Care (FRA:TD5A) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Tandem Diabetes Care's annualized ROC % for the quarter that ended in Dec. 2023 is calculated as:

	ROC % (Q: Dec. 2023 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Sep. 2023 )	+	Invested Capital (Q: Dec. 2023 ))	/ count )
=	-128.6 * ( 1 - 4.18% )	/	( (357.5	+	387.372)	/ 2 )
=	-123.22452	/	372.436
=	-33.09 %

where

	Invested Capital		(Q: Sep. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	880.695	-	56.421	-	( 466.774	-	max(0, 175.322	-	710.381	+	466.774	))
=	357.5

	Invested Capital		(Q: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	873.587	-	57.14	-	( 429.075	-	max(0, 179.052	-	685.906	+	429.075	))
=	387.372

Note: The Operating Income data used here is four times the quarterly (Dec. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Tandem Diabetes Care's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Dec. 2023 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Sep. 2023		Q: Dec. 2023
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-110.456	/	( ( (154.787 + max(84.793, 0))	+	(150.693 + max(93.423, 0)) )	/	2 )
=	-110.456	/	( ( 239.58	+	244.116 )	/	2 )
=	-110.456	/	241.848
=	-45.67 %

where Working Capital is:

	Working Capital		(Q: Sep. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(93.998	+	134.452	+	15.157)	-	(56.421	+	29.619	+	72.774)
=	84.793

	Working Capital		(Q: Dec. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(96.794	+	144.828	+	15.209)	-	(57.14	+	40.342	+	65.926)
=	93.423

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Tandem Diabetes Care's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Dec. 2023 )
	=	-197.433	/	2185.471
	=	-9.03 %

Tandem Diabetes Care EBIT Related Terms

Thank you for viewing the detailed overview of Tandem Diabetes Care's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Tandem Diabetes Care (FRA:TD5A) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Tandem Diabetes Care Inc (FRA:TD5A) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

TNDM:USA

Address

11075 Roselle Street, San Diego, CA, USA, 92121

Website

https://www.tandemdiabetes.com

Tandem Diabetes designs, manufactures, and markets durable insulin pumps for diabetes patients. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. Nearly three quarters of total revenue is derived from the U.S., with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one third is from disposable infusion sets that need to be changed over every 2 to 3 days.

Tandem Diabetes Care (FRA:TD5A) Headlines

No Headlines